Lubiprostone is a drug commonly used to treat chronic idiopathic constipation, which was approved for this purpose in 2006 in the United States of America.[2] The researchers discovered an unexpected link between constipation and a decline in kidney function, which led them to test the potential protective effect of lubiprostone on the kidneys. The study examined the safety of this drug in the context of protecting kidney function.[2] The results suggest that lubiprostone may have a positive effect on kidney protection. Researchers have identified a therapy targeting the gut system and mitochondria as a promising new option in chronic kidney disease (CKD) care. These findings represent a potentially new approach to treating patients with kidney problems through modulation of intestinal function.